.png)
GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, oncology cell therapy, tumor cell targeting and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
